1.
Comparison of Study Designs for Primary Phase III Trials for Omalizumab Versus Dupilumab for Patients With Chronic Spontaneous Urticaria. J of Skin [Internet]. 2023 Nov. 13 [cited 2025 Apr. 7];7(6):s299. Available from: https://skin.dermsquared.com/skin/article/view/2367